Sign Out
Click on icon to see table/diagram/imageSpecial populations: One dose of Vaxneuvance may be given to individuals who have one or more underlying conditions predisposing them to an increased risk of pneumococcal disease (such as individuals with sickle cell disease, living with human immunodeficiency virus (HIV) infection or immunocompetent individuals 18 to 49 years of age with risk factors for pneumococcal disease; see Pharmacology: Pharmacodynamics under Actions).
Method of administration: The vaccine should be administered by intramuscular injection. The preferred site is the anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in children and adults.
No data are available for administration via the subcutaneous or intradermal routes.
For instructions on the handling of the vaccine before administration, see Special precautions for disposal and other handling under Cautions for Usage.
